-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Travere Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from Q1 2012 to Q1 2025.
- Travere Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $3.72M.
- Travere Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $139M, a 36.3% decline from 2023.
- Travere Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $219M, a 86.1% increase from 2022.
- Travere Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $118M, a 49.3% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)